RxDoctor Payments Data

Gregory Buser, MD

Clinical Cardiac Electrophysiology · San Antonio, TXNPI 1548280407

Payments from drug & device makers

$2,374in general payments, 2019–2025

Across 73 payments — averaging $32.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Medtronic$407
  • Johnson & Johnson$154
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$134
  • Novartis$93
  • Irhythm Technologies, Inc.$57
  • plus $233 from 9 others

What the payments were for

  • Travel & lodging$67528%
  • Food & beverage$1,68771%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,374 in reported general payments places this provider in the 0th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$183,994
Medicare patients
798
Services billed
2,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban289$326,292
XareltoRivaroxaban130$156,617
MultaqDronedarone Hcl37$66,505
EntrestoSacubitril/Valsartan40$50,977
Repatha SureclickEvolocumab31$25,717
Propafenone Hcl ErPropafenone Hcl30$6,626
Rosuvastatin Calcium230$3,663
Flecainide Acetate62$2,334
Atorvastatin Calcium209$2,074
Losartan Potassium199$1,887
Metoprolol Succinate120$1,834
Chlorthalidone66$1,442
Ezetimibe54$1,437
Carvedilol172$1,415
Amiodarone Hcl80$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$154$156,617130 claims
Sanofi-aventis U.S. LLCMultaq$13$66,50537 claims
NovartisEntresto$93$50,97740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →